Navigation Links
Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes
Date:9/10/2009

MINNEAPOLIS, Sept. 10 /PRNewswire/ -- Exsulin Corporation today announced the start of a phase II human clinical trial of Exsulin(TM), a peptide drug product aimed at restoring insulin production in people with diabetes mellitus. The randomized, controlled 12-week trial in patients with established Type 1 diabetes (T1DM) will be co-led by Mayo Clinic in Rochester, Minn., and McGill University Health Centre in Montreal, Canada. First results are expected to be available in Q2 2010. The design of the study is based on previous trials which showed improvement in insulin secretion and glucose control in both Type 1 and Type 2 diabetes (T2DM) patients treated with Exsulin.

Diabetes is a life-threatening condition affecting nearly 24 million people in the United States, and more than 200 million worldwide. It remains one of medicine's most significant and costly chronic diseases, and its prevalence is expected to grow due to the global obesity epidemic and the aging of the population. T1DM develops when the body's immune system destroys pancreatic beta cells that make insulin, the key hormone responsible for controlling blood sugar levels. All people with T1DM require insulin therapy to survive. People with T2DM have insufficient insulin secretion and uptake, and often require insulin therapy as their disease progresses. Poorly controlled diabetes can lead to serious complications, including blindness, kidney failure and death.

"Exsulin is a hormone that is being studied for its potential ability to regenerate islets - and possibly restore insulin production -- in the pancreas," said G. Alexander Fleming, MD, founder and chairman, Exsulin Corporation. "We look forward to the results of this important study, which will build on previous findings and further characterize the effects of Exsulin on insulin production and glucose control."

"This phase II tri
'/>"/>

SOURCE Exsulin Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today announced that the Company achieved ... Good Manufacturing Practice (GMP) certificate of TPI,s Qionglai ... Administration,s (CFDA). The public notice period is a ...
(Date:12/24/2014)...  Medical Science Liaisons play a large role in ... medical device industry and key stakeholders, the role of ... as the device industry relies on them to build ... benchmarking firm, Best Practices, LLC, one area where Medical ... by harnessing new technology to enable education. Online conferences ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... 21, 2010 Reportlinker.com announces that a new ... Thai Self-monitoring of Blood Glucose ... http://www.reportlinker.com/p0350305/Thai-Self-monitoring-of-Blood-Glucose-SMBG-Devices-and-Strips-Market.html This Market Engineering ... dynamics of blood glucose monitoring device sales and ...
... 2010 The American Veterinary Medical Association (AVMA) has offered ... on a useful and effective induction agent, propofol. ... Schedule IV drug.  In a letter to the DEA today, ... this effective drug, which typically causes few side effects when ...
Cached Medicine Technology:AVMA Offers Important Guidance to DEA on New Controls for Induction Agent—Propofol 2
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, iFitDress.com, the ... for women, has announced its new selection of black ... are on sale now; they are available at discounted prices, ... says, “The promotion will last for three weeks only. You ... market. Those who are interested in our new items can ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... Plan focuses on added benefits to improve care ... with chronic health conditions -, LITTLE ROCK, ... Medicare annual enrollment period which begins November 15th, ... 2009 Special Needs Plan,(SNP) offerings for chronically ill ...
... Points to Need for a Federal Office of Men,s ... national,phone and direct mail effort, was administered to the ... Washington, D.C.) and,the Governor,s Office, where appropriate. The survey ... Meeting in San,Diego on October 26th, 2008 and are ...
... of the National Organization for Rare Disorders ... Compassionate Allowances,initiative "an outstanding achievement" that will ... The initiative announced today will fast-track applications ... of 25 rare diseases and 25,cancers whose ...
... NANJING, China, Oct. 27 /Xinhua-PRNewswire/ -- Simcere ... manufacturer and supplier of branded generic,pharmaceuticals and ... market, announced today its participation in the ... conference will be,held at the Grand Hyatt ...
... led by UBC Psychiatry Prof. Weihong Song, who is also ... Disease at UBC, found that if Valproic Acid (VPA) is ... deficit is reversed. , The study, published in the Journal ... activity of an enzyme that produces a neurotoxic protein called ...
... Readers to Meaningful Coincidences, LOUISVILLE, Colo., Oct. ... Clearly Now: How Synchronicity Illuminates Our,Lives, has been ... in both Best New,Non-Fiction and Best New Age ... USABookNews.com, the premiere online magazine and review ...
Cached Medicine News:Health News:Care Improvement Plus Launches 2009 Benefits in Arkansas 2Health News:New State Public Health Department Survey Results Highlight Available Resources for Men and Women 2Health News:New Compassionate Allowances for Social Security Disability Represent 'Outstanding Achievement,' NORD Says 2Health News:Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008 2Health News:New Author Mary Soliel Honored as Two-time National Best Books 2008 Award Finalist 2
... The OcuLight family of infrared laser photocoagulators ... models. These diode lasers serve as a ... and applications, require no regular maintenance or ... their compact design. The OcuLight SLx is ...
... Using the latest in solid-state technology, ... green light at 532 nm. Patented ... delivery device options maximize versatility, compact ... and advanced design minimizes any routine ...
... Danker Laboratories manufacturers a ... orthokeratology lenses (also known ... "Corneal Reshaping" Lenses) according ... and demanding standards of ...
... The Euclid Systems Orthokeratology (oprifocon A) ... contact lenses used for orthokeratology, a ... The patient wears these lenses overnight ... During the day, nearsightedness is temporarily ...
Medicine Products: